Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report

Chen,Zhiheng; Guan,Hong; Yuan,Hong; Cao,Xia; Liu,Yingxin; Zhou,Ji; He,Ellen; Skog,Sven

doi:10.3892/ol.2015.3440

Serum thymidine kinase 1 is a reliable maker for the assessment of the risk of developing malignancy: A case report

Authors:
- Zhiheng Chen
- Hong Guan
- Hong Yuan
- Xia Cao
- Yingxin Liu
- Ji Zhou
- Ellen He
- Sven Skog
View Affiliations

Affiliations: Health Management Centre, Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Pathology, Shenzhen Second Hospital, Shenzhen, Guangdong 322000, P.R. China, Research Center of Sub‑Health's Diagnose and Intervention Technology and Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Sino‑Swed Molecular Bio‑Medicine Research Institute, Shenzhen, Guangdong 518057, P.R. China
Published online on: June 30, 2015 https://doi.org/10.3892/ol.2015.3440
Pages: 1669-1673

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

With regard to different types of malignancies, thymidine kinase 1 (TK1) is a useful prognostic marker in clinical oncology, both as a serum proliferation marker and in immunohistochemistry. The present study investigated the use of serum TK1 protein (STK1p) for the identification of multiple proliferating diseases linked to the risk of developing cancer, by following one patient during the period of 2003‑2014. The patient presented with adenomatous polyps in the stomach in 2003, follicular cervicitis in 2007 and hyperplasia of the breast/fibrocystic breasts in 2010. The breast cysts increased from 4x5 mm in size in 2010 to 8x7 mm in size in 2013, and were assessed as a suspicious malignancy at the end of this period. In parallel, the STK1p values increased from 2.0 to 7.6 pM. Based on this information, a minimally invasive surgery using the Mammotome® Biopsy System was performed. Immunohistochemistry on the cyst tissue showed strong staining of TK1 in the ductal epithelial cells and thus confirmed the abnormal proliferation in the lesion. One week after the surgery, the STK1p value had decreased to almost normal values (1.6 pM), but then fluctuated above 2.0 pM for the next 7 months. After the surgery, the patient was re‑examined and small foci with squamous cell hyperplasia and a suspected ulcerated cervix, as well as flat gastric erosive, were identified, but not treated; this may explain why the STK1 P‑values did not return to within normal values. The patient is currently being followed up using STK1p analysis combined with imaging/pathology in order to begin therapeutic intervention as early as possible to avoid the risk of developing cancer. Overall, STK1p is useful in health screening to identify individuals at risk of developing premalignancy/malignancy.

View Figures

View References

1	Chen Z, Zhou H, Li S, He E, Hu J, Zhou J and Skog S: Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumours. Anticancer Res. 28:3897–3907. 2008.PubMed/NCBI
2	Huang S, Lin J, Guo N, Zhang M, Yun X, Liu S, Zhou J, He E and Skog S: Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev. 12:497–505. 2011.PubMed/NCBI
3	Sherley JL and Kelly TJ: Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 263:8350–8358. 1988.PubMed/NCBI
4	Kauffman MG and Kelly TJ: Cell cycle regulation of thymidine kinase: Residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol. 11:2538–2546. 1991.PubMed/NCBI
5	He Q, Zhang P, Li Z, Li H, Wang X, Zou S, Fornander T and Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep. 14:1013–1019. 2005.PubMed/NCBI
6	Welin M, Kosinska U, Mikkelsen NE, Carnrot C, Zhu C, Wang L, Eriksson S, Munch-Petersen B and Eklund H: Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci USA. 101:17970–17975. 2004. View Article : Google Scholar : PubMed/NCBI
7	He Q, Zou L, Zhang PA, Liu JX, Skog S and Fornander T: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. J Biol Marker. 15:139–146. 2000.
8	Wu CJ, Yang R, Zhou J, Bao S, Zou L, Zhang P, Mao Y, Wu J and He Q: Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immuno Methods. 277:157–169. 2003. View Article : Google Scholar
9	He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE and Skog S: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 26:4753–4759. 2006.PubMed/NCBI
10	Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A and Schwentner C: Thymidine kinase and cancer monitoring. Cancer Lett. 316:6–10. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhou J, He E and Skog S: The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 1:18–28. 2013.PubMed/NCBI
12	Xu XH, Zhang YM, Shu XH, Shan LH, Wang ZW, Zhou YL, Wen HK, He F, He E and Skog S: Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Rep. 1:705–712. 2008.PubMed/NCBI
13	Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB, Wang YH, He E, et al: Serological thymidine kinase 1 is a biomarker for early detection of tumours-a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors(Basel). 11:11064–11680. 2011. View Article : Google Scholar : PubMed/NCBI
14	Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, He E, Eriksson S, Wen W and Skog S: Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumour therapy management. Mol Med Reports. 2:923–929. 2009.
15	Ang YK, Mirnalini K and Zalilah MS: A workplace email-linked website intervention for modifying cancer-related dietary and lifestyle risk factors: Rationale, design and baseline findings. Malays J Nutr. 19:37–51. 2013.PubMed/NCBI
16	Sulaiman S, Shahril MR, Wafa SW, Shaharudin SH and Hussin SN: Dietary carbohydrate, fiber and sugar and risk of breast cancer according to menopausal status in malaysia. Asian Pac J Cancer Prev. 15:5959–5964. 2014. View Article : Google Scholar : PubMed/NCBI
17	Berman JJ and Moore GW: Part I, Limitation of Current Approaches to Cancer Treatment; Part II, Precancer Pathology and Biology; Part III, Eradication of Cancer By Treatment of PrecancerPrecancer: The Beginning and the End of Cancer. Jones and Bartlett Publishers; Sudbury, MA, USA: pp. 1–113. 2010
18	Pandey S and Chandravati: Breast screening in north India: A cost-effective cancer prevention strategy. Asian Pac J Cancer Prev. 14:853–857. 2013. View Article : Google Scholar : PubMed/NCBI
19	Cigna, . Tumor markers for cancer. http://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0172_coveragepositioncriteria_tumor_markers_for_diagnosis_mgmt_cancer.pdfAccessed on. January 1–2015
20	Underwood JCE: Classification of tumoursGeneral and Systematic Pathology. Elsevier Ltd.; pp. 227–229. pp. 240–235. pp. 374–473. pp. 4972004